On December 3, 2024, Rosty Raykov, Director at Fennec Pharmaceuticals Inc (FENC, Financial), sold 1,635 shares of the company. Following this transaction, the insider now owns 67,228 shares of the company. The details of this transaction can be found in the SEC Filing.
Fennec Pharmaceuticals Inc (FENC) is a biopharmaceutical company focused on the development of product candidates for the treatment of cancer. The company's lead product candidate is PEDMARKâ„¢, a formulation of sodium thiosulfate, which is in development to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients.
The insider transaction history for Fennec Pharmaceuticals Inc shows that there have been 0 insider buys in total over the past year. Meanwhile, there have been 23 insider sells over the same timeframe. Over the past year, Rosty Raykov has sold 151,475 shares in total and purchased 0 shares in total.
On the day of the recent sell, shares of Fennec Pharmaceuticals Inc were trading for $6.13 apiece. This gives the stock a market cap of $160.596 million. Investors may consider various valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow when evaluating the stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
